Avidity Biosciences Net Worth
Avidity Biosciences Net Worth Breakdown | RNA |
Avidity Biosciences Net Worth Analysis
Avidity Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Avidity Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Avidity Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Avidity Biosciences' net worth analysis. One common approach is to calculate Avidity Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Avidity Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Avidity Biosciences' net worth. This approach calculates the present value of Avidity Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Avidity Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Avidity Biosciences' net worth. This involves comparing Avidity Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Avidity Biosciences' net worth relative to its peers.
To determine if Avidity Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Avidity Biosciences' net worth research are outlined below:
| Avidity Biosciences had very high historical volatility over the last 90 days | |
| The company reported the last year's revenue of 10.9 M. Reported Net Loss for the year was (322.3 M) with loss before taxes, overhead, and interest of (292.7 M). | |
| Avidity Biosciences has about 398.22 M in cash with (300.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.64. | |
| Over 95.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Avidity Biosciences Buy Rating Reiterated at HC Wainwright |
Avidity Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Avidity Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Avidity Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Avidity Biosciences Target Price Consensus
Avidity target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Avidity Biosciences' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 11 | Strong Buy |
Most Avidity analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Avidity stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Avidity Biosciences, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAvidity Biosciences Target Price Projection
Avidity Biosciences' current and average target prices are 30.84 and 68.27, respectively. The current price of Avidity Biosciences is the price at which Avidity Biosciences is currently trading. On the other hand, Avidity Biosciences' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Avidity Biosciences Market Quote on 21st of March 2025
Target Price
Analyst Consensus On Avidity Biosciences Target Price
Know Avidity Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Avidity Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Avidity Biosciences backward and forwards among themselves. Avidity Biosciences' institutional investor refers to the entity that pools money to purchase Avidity Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Adage Capital Partners Gp Llc | 2024-12-31 | 2.8 M | Casdin Capital, Llc | 2024-12-31 | 2 M | Boxer Capital Management, Llc | 2024-12-31 | 1.7 M | Boxer Capital Llc | 2024-09-30 | 1.7 M | Polar Capital Holdings Plc | 2024-12-31 | 1.3 M | Driehaus Capital Management Llc | 2024-12-31 | 1.2 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.2 M | Siren, L.l.c. | 2024-12-31 | 1.1 M | Orbimed Advisors, Llc | 2024-12-31 | 1.1 M | Fmr Inc | 2024-12-31 | 16.5 M | T. Rowe Price Associates, Inc. | 2024-12-31 | 11 M |
Follow Avidity Biosciences' market capitalization trends
The company currently falls under 'Mid-Cap' category with a total capitalization of 3.71 B.Market Cap |
|
Project Avidity Biosciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.21) | (0.22) | |
| Return On Capital Employed | (0.26) | (0.25) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.23) | (0.21) |
When accessing Avidity Biosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Avidity Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Avidity Biosciences' profitability and make more informed investment decisions.
Please note, the presentation of Avidity Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Avidity Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Avidity Biosciences' management manipulating its earnings.
Evaluate Avidity Biosciences' management efficiency
Avidity Biosciences has Return on Asset of (0.2161) % which means that on every $100 spent on assets, it lost $0.2161. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.3347) %, meaning that it generated no profit with money invested by stockholders. Avidity Biosciences' management efficiency ratios could be used to measure how well Avidity Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of March 21, 2025, Return On Tangible Assets is expected to decline to -0.22. The current year's Return On Capital Employed is expected to grow to -0.25. At present, Avidity Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 42.8 M, whereas Other Assets are forecasted to decline to 0.86.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 12.77 | 13.41 | |
| Tangible Book Value Per Share | 12.77 | 13.41 | |
| Enterprise Value Over EBITDA | (8.00) | (8.40) | |
| Price Book Value Ratio | 2.28 | 2.39 | |
| Enterprise Value Multiple | (8.00) | (8.40) | |
| Price Fair Value | 2.28 | 2.39 | |
| Enterprise Value | 537 M | 477.3 M |
Leadership effectiveness at Avidity Biosciences is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Enterprise Value Revenue 202.9411 | Revenue | Quarterly Revenue Growth 0.356 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Avidity Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Avidity Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Avidity Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Avidity Biosciences Corporate Filings
8K | 17th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 12th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Avidity Biosciences Earnings Estimation Breakdown
The calculation of Avidity Biosciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Avidity Biosciences is estimated to be -0.8803 with the future projection ranging from a low of -1.071 to a high of -0.55. Please be aware that this consensus of annual earnings estimates for Avidity Biosciences is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.07 Lowest | Expected EPS | -0.55 Highest |
Avidity Biosciences Earnings Projection Consensus
Suppose the current estimates of Avidity Biosciences' value are higher than the current market price of the Avidity Biosciences stock. In this case, investors may conclude that Avidity Biosciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Avidity Biosciences' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 13 | 97.61% | -0.8 | -0.8803 | -2.89 |
Avidity Biosciences Earnings History
Earnings estimate consensus by Avidity Biosciences analysts from Wall Street is used by the market to judge Avidity Biosciences' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Avidity Biosciences' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Avidity Biosciences Quarterly Gross Profit |
|
Avidity Biosciences Earnings per Share Projection vs Actual
Actual Earning per Share of Avidity Biosciences refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Avidity Biosciences predict the company's earnings will be in the future. The higher the earnings per share of Avidity Biosciences, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Avidity Biosciences Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Avidity Biosciences, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Avidity Biosciences should always be considered in relation to other companies to make a more educated investment decision.Avidity Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Avidity Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-26 | 2024-12-31 | -0.7809 | -0.8 | -0.0191 | 2 | ||
2024-11-06 | 2024-09-30 | -0.71 | -0.65 | 0.06 | 8 | ||
2024-08-09 | 2024-06-30 | -0.79 | -0.65 | 0.14 | 17 | ||
2024-05-09 | 2024-03-31 | -0.78 | -0.79 | -0.01 | 1 | ||
2024-02-28 | 2023-12-31 | -0.66 | -0.79 | -0.13 | 19 | ||
2023-11-08 | 2023-09-30 | -0.77 | -0.71 | 0.06 | 7 | ||
2023-08-08 | 2023-06-30 | -0.8 | -0.66 | 0.14 | 17 | ||
2023-05-09 | 2023-03-31 | -0.85 | -0.74 | 0.11 | 12 | ||
2023-02-28 | 2022-12-31 | -0.89 | -0.88 | 0.01 | 1 | ||
2022-11-08 | 2022-09-30 | -0.93 | -0.82 | 0.11 | 11 | ||
2022-08-09 | 2022-06-30 | -0.75 | -0.92 | -0.17 | 22 | ||
2022-05-10 | 2022-03-31 | -0.8 | -0.71 | 0.09 | 11 | ||
2022-03-01 | 2021-12-31 | -0.7 | -0.82 | -0.12 | 17 | ||
2021-11-09 | 2021-09-30 | -0.68 | -0.68 | 0.0 | 0 | ||
2021-08-09 | 2021-06-30 | -0.71 | -0.7 | 0.01 | 1 | ||
2021-05-12 | 2021-03-31 | -0.56 | -0.64 | -0.08 | 14 | ||
2021-03-15 | 2020-12-31 | -0.34 | -0.43 | -0.09 | 26 | ||
2020-11-10 | 2020-09-30 | -0.37 | -0.31 | 0.06 | 16 | ||
2020-08-10 | 2020-06-30 | -0.24 | -1.23 | -0.99 | 412 | ||
2014-09-30 | 2014-09-30 | -0.23 | -0.29 | -0.06 | 26 | ||
2014-06-30 | 2014-06-30 | -0.25 | -0.22 | 0.03 | 12 | ||
2014-03-31 | 2014-03-31 | -0.03 | 0.19 | 0.22 | 733 | ||
2013-12-31 | 2013-12-31 | -0.12 | -0.11 | 0.01 | 8 |
Avidity Biosciences Corporate Management
| Kathleen Gallagher | Chief Officer | Profile | |
| Teresa McCarthy | Chief Officer | Profile | |
| Eric Mosbrooker | Chief Officer | Profile | |
| III JD | Consultant | Profile | |
| Michael CPA | Chief Officer | Profile | |
| Michael MacLean | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Avidity Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Avidity Stock refer to our How to Trade Avidity Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avidity Biosciences. If investors know Avidity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avidity Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.89) | Revenue Per Share | Quarterly Revenue Growth 0.356 | Return On Assets | Return On Equity |
The market value of Avidity Biosciences is measured differently than its book value, which is the value of Avidity that is recorded on the company's balance sheet. Investors also form their own opinion of Avidity Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Avidity Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avidity Biosciences' market value can be influenced by many factors that don't directly affect Avidity Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avidity Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avidity Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avidity Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.